Our next-generation T-Cell priming vaccine candidates have the potential to tackle major global diseases and can offer efficacy against a range of viral pathogens including Dengue, Coronavirus Influenza, Zika, Yellow fever, as well as intracellular bacteria.
We also have programmes in development for a universal Influenza (flu) vaccine, a universal Filovirus vaccine (to target viruses including Ebola and Marburg), a Yellow Fever Booster vaccine, and a Chikungunya virus vaccine.
We are also working on vaccines for several intracellular bacterial infections, such as Francisella tularensis, currently categorized as a Tier 1 biothreat priority by the US government.
We have partnered with the IMCB of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease.
